NovaMed is a revenue-generating specialty pharmaceutical company focused on commercialization of branded therapies for diseases with high unmet medical need. The Company is a value-added partner providing broad commercialization experience with an expertise ranging from clinical development product registration and importation to sales and marketing.
Missing: NovaMed's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: NovaMed's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
NovaMed has filed 1 patent.
Laboratory equipment, Fluid dynamics, Medical terminology, Blood tests, Chemical tests
Laboratory equipment, Fluid dynamics, Medical terminology, Blood tests, Chemical tests
Latest NovaMed News
Sep 27, 2021
Loop News NovaMed was founded by medical doctor David Walcott (pictured) and entrepreneur Kirk Hamilton. Windward Medical Centre (InterMed Co) was recently awarded grant funding of $13 million from the Development Bank of Jamaica (DBJ) through its Innovation Grant Fund specifically targeted at boosting innovation, growth and entrepreneurship ecosystems for SMEs. The DBJ has been instrumental in and has been the catalyst in facilitating the growth and development of Jamaicans and recently launched the Innovation Grant Fund (IGF) for medium–sized enterprises under the Boosting Innovation Growth & Entrepreneurship Ecosystems (BIGEE). “Under the DBJ Innovation Grant Fund we are endeavouring to ensure that Jamaican medium-sized companies that are doing exceptional work in transforming their operation using technology and innovative methods have access to grants and funding to assist them”, states Milverton Reynolds, Managing Director, DBJ. “And so, we would like to congratulate the team at Windward Medical Centre for the innovative and groundbreaking work that they are doing in this area”. The medical centre, which caters to persons in and around the community off Windward Road has been in operation for over 30 years and is now a part of the portfolio of companies for NovaMed - a healthcare innovation company based in Jamaica with a mandate to deliver world-class healthcare services to emerging markets. NovaMed was founded by medical doctor David Walcott and entrepreneur Kirk Hamilton. According to Walcott, the grant funding from the DBJ will primarily be used to execute the T.O.P Initiative, which focuses on a transformative approach through Technology, Operating Capacity Expansion (surgical & infrastructural) and Preventative Community Care. Additionally, the company will utilise part of the funding to digitize its healthcare offering through the implementation of an EMR software with clinical insight and artificial-intelligence-driven decision-making capability to optimize health care decisions around patients. Windward Medical will also outfit its surgical centre with equipment designed to allow the medical centre to fill the unserved surgical needs of its clientele, as well as launch a series of community engagement initiatives targeted at promoting health literacy and preventative care. “Our service delivery is premised on our ability to accelerate innovation in healthcare by bringing multiple innovative healthcare practices and partnerships to emerging markets to facilitate holistic change across health economies”, Walcott said. The medical doctor and businessman noted that currently Windward Medical’s ability to serve low-income populations and optimize patient outcomes is limited by challenges endemic to the primary healthcare system in Jamaica. He shared that some of these challenges include low levels of resources, low-purchasing power of patients and relatively low health literacy of patients which often lead to poor healthcare decision-making. With the funding capital, Walcott said the medical centre will be able to design a healthcare delivery model that optimizes patient outcomes and manages costs. “We anticipate that our three-pronged solution of our T.O.P Initiative will take us one step further in delivering world-class healthcare delivery and solutions to emerging markets”, Walcott said. Download the Loop News Caribbean app to keep up to date with all the latest news right in the palm of your hand. Related Articles
NovaMed Frequently Asked Questions (FAQ)
Where is NovaMed's headquarters?
NovaMed's headquarters is located at 5501 West Gray Street, Tampa.
What is NovaMed's latest funding round?
NovaMed's latest funding round is Acquired.
Who are the investors of NovaMed?
Investors of NovaMed include Surgery Partners, Atlas Venture, F-Prime Capital and Fidelity Investments.
Who are NovaMed's competitors?
Competitors of NovaMed include EUSA Pharma, CytImmune Sciences, Aegerion Pharmaceuticals, NextWave Pharmaceuticals, AkaRx, Ikaria, GC-Rise Pharmaceutical, IVERIC bio, Somaxon Pharmaceuticals, Neovacs and 14 more.
Compare NovaMed to Competitors
Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a highly selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.
Indena is a company dedicated to the identification, development and production of active principles derived from plants, for use in the pharmaceutical, health-food and cosmetics industries. Indena, a privately owned Italian company, has around 700 employees, including 10% dedicated to full-time research, aims to manage cultivation, manufacturing, and distribution operations in more than 40 countries throughout the world. The key to Indena's success is its research, covering: the screening of medicinal plants for their pharmacological benefits; the identification of new active principles; and the development of extraction and purification systems at the cutting-edge of industrial application. The phyto-chemical research is carried out in Indena's own Research Center in Settala, Italy. Indena also co-operates with the world's most prestigious universities and private research institutions in the biological assessment of safety and effectiveness up to clinical phase I. One of the main strategic objectives of the research is the development of new active principles for pharmaceutical applications. This is also an indispensable base for the health-food and cosmetics industries. In the pharmaceutical sector Indena is currently focusing on the development of anti-cancer treatments, following the successes of paclitaxel, as well as on anti-microbial and on anti-viral drugs. Also under study are active principles for the treatment of pathologies and dysfunction of the central nervous system, such as depression, anxiety, impotence, sleep disorders, and algesia. Today Indena is also concentrating its efforts on the industrial production of high-quality standardised active principles derived from plants, which are important ingredients in health food products. In fact, the company produces standardised extracts from edible plants that are traditionally recognised as having therapeutic properties, as well as from plants that have proven pharmacological value. Indena's research and production activities are particularly attentive to plant-based principles that have anti-oxidant properties and are effective in preventing damage caused by free radicals. Backed by over 80 years of botanical experience, the Italian company has developed a plantation network, managed by experts, to supply its research and production centers with officinal plants, while at the same time ensuring bio-diversity and protecting the ecosystem balance from uncontrolled harvesting. Today more than 60% of the raw material used in the manufacturing process comes from cultivation. Indena's decades-long global presence in the plant extraction industry is a guarantee of its in-depth knowledge and understanding of the business, market trends and legal considerations, through constant communication and interaction between the company's experts and the major international regulatory authorities such as WHO, EMEA, and ESCOP, and main pharmacopoeias.
Pharmaceutical Company in China
A European specialty pharmaceutical company dedicated to hospital and specialist drugs.SpePharm is a European specialty pharmaceutical company focused on acquiring, registering and marketing high medical value specialty medicines, essentially for the hospital market.
ENTRA Pharmaceuticals is a specialty pharmaceutical company developing therapies and improving existing treatments in areas with high unmet medical needs. In addition to the company's technology platform, ENTRA possesses strong expertise in preclinical and clinical drug development and commercialization.
IVREA Pharmaceuticals is a specialty pharmaceutical company focused on clinical development and commercialization of novel prescription pharmaceuticals for the treatment of dermatologic conditions. IVREA's pharmaceuticals leverage topical delivery technologies.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.